Researchers have identified key distinctions in multiple sclerosis lesions that can indicate whether patients can benefit from a therapy called plasma exchange. Only those patients whose lesions include evidence of antibody deposition or immune cell activity called "complement activation" are likely to respond to the plasma exchange treatment for acute attacks, according to the study.

Full Story:

Related Summaries